---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-043497"
form_type: "8-K"
ticker: "CGON"
cik: "0001991792"
company_name: "CG Oncology, Inc."
filed_at: "2025-03-24T23:59:59+00:00"
generated_at: "2026-05-24T07:01:23.509020+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# CG Oncology reports 75.5% complete response rate in Phase 3 bladder cancer trial; median DOR >28 months

## Summary
- 83 of 110 patients (75.5%) achieved complete response at any time in BOND-003 for BCG-unresponsive NMIBC with CIS.
- Median duration of response not reached but exceeds 28 months; 46% in CR at 12 months.
- No Grade 3+ treatment-related adverse events or deaths; 97.3% completed all expected treatments.
- Translational data show no systemic exposure, eliminating need for close contact precautions post-treatment.
- Data presented as late-breaking abstract at 40th Annual EAU Congress in Madrid.

## SEC filing metadata
- accession: 0000950170-25-043497
- form_type: 8-K
- ticker: CGON
- cik: 0001991792
- company_name: CG Oncology, Inc.
- filed_at: 2025-03-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1991792/000095017025043497/0000950170-25-043497-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1991792/000095017025043497/ck0001991792-20250324.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-043497
- JSON: https://secwatch.observer/filing/0000950170-25-043497.json
- Plain text: https://secwatch.observer/filing/0000950170-25-043497.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.